🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We’re proud to be recognized as one of the Top #Biotech Startups by Life Sciences Review! It’s an honor to be named among the best. This reaffirms our mission to develop non-viral, #geneticmedicines to treat and potentially cure serious diseases: bit.ly/3V1Ag7u

We received a shout-out from @BionestPartners in their review of #genetherapies and the various delivery strategies being developed in the #raredisease space. Learn more about our 3DNA® Platform and what makes it different: bit.ly/3HPS5RJ

We’re thrilled to be named the “Healthcare Innovator” award winner at the 30th Annual Philadelphia Alliance for Capital & Technologies Enterprise Awards. To be recognized as a leader in the #lifescience and #biotech industry is an honor. Congrats to all the finalists!

Going to #BIO2023? Keep an eye out for our CSO, Dave Anderson, Ph.D. He will present an update on our novel 3DNA platform, while our CEO Brian McVeigh and CBO, Lauren M. Kaskiel, MBA will also be in #Boston for the Biotechnology Innovation Organization Convention. bit.ly/3Cb2jZt #IAmBIO

We're excited to be featured in Innovation Tech News Startup Showcase! The article highlights how we’re revolutionizing the field of precision #geneticmedicine with our novel #DNA delivery platform, 3DNA®. Read more: bit.ly/3BPcWkE

Code Bio was featured in an article by nature Biotechnology about the opportunities and challenges in the field of #geneticmedicine. Learn how our platform, 3DNA, enables precise targeting of organs and specific cells: rdcu.be/dezRc #innovation

We're excited to attend the Next Generation Gene Therapy Vectors Summit to discuss precision #geneticmedicine! Our CPTO Robert Getts will provide an overview of our 3DNA® platform, its advantages & how we're developing a new class of genetic medicines: bit.ly/3JnTujj

Our non-viral #3DNA® platform ensures precise delivery of #GeneTherapy, RNAi, and other genetic treatments. Discover how it works: bit.ly/3XsOTBY

#ICYMI: Our CSO, Dave Anderson presented on our novel 3DNA platform at #BIO2023. He discussed how we’re pioneering an era of change in the delivery of transformational, non-viral #geneticmedicine. Learn more about our 3DNA platform: bit.ly/3XsOTBY

Our CEO Brian McVeigh was interviewed as part of the WuXi AppTec “BOLD” online series discussing how Code Bio is pioneering a new class of #geneticmedicines to enable the precise and targeted delivery of treatments via our novel DNA delivery platform 3DNA bit.ly/3YfmTSK

We were thrilled to be interviewed by WuXi AppTec about how we’re developing a new class of precise #geneticmedicines. We’re excited to continue to gain more knowledge that will help us drive medicines to cells that need to be treated.

Our non-viral #3DNA® platform facilitates the precise delivery of #geneticmedicine by enabling the targeting of organs and cells specifically associated with the disease. Here’s how it works: bit.ly/3XsOTBY

CEO, Brian McVeigh is moderating the “Managing the Runway” panel at the Longwood Healthcare Leaders conference on September 19. The event brings together #BioPharma leaders in a networking and brainstorming forum. #LongwoodHealthcareLeaders bit.ly/3QZD1GA

Join Code Bio at the Life Science Cares Philadelphia Mini Golf FUN-raiser on September 21 at 4 pm. All funds raised support LSC PHL's grant-making efforts in support of nonprofit partners. Register here: bit.ly/3R1lFJw

Our Chief Scientific Officer, David Anderson, is presenting for Code Bio at Chardan's Genetic Medicines Conference. This conference highlights genetic medicines through fireside chats, presentations and panel discussions: bit.ly/3LIc7zl #CGMC2023 #ChardanGMConf

Our CSO, Dave Anderson, and CBO, Lauren Kaskiel represented Code Bio at the ESGCT 30th Annual Congress! Check out these behind-the-scenes snapshots as they network and collaborate with industry leaders. #ESGCT

Code Bio recently hosted a #fooddrive in collaboration with Manna on Main Street, an organization committed to ending hunger in the North Penn region. As a result of our team’s incredible support, we donated 408 pounds of food that will help feed members of our community in need.

We’re thrilled to be attending the J.P. Morgan Healthcare Conference in a few weeks! We are looking forward to sharing our progress in developing our novel non-viral 3DNA platform and pipeline that overcomes current #geneticmedicine delivery challenges. See you there! #JPM24

Our CEO, Brian McVeigh will be sharing his experience at the Goodwin & KPMG US 5th Annual Symposium during the J.P. Morgan Healthcare Conference. Learn more: bit.ly/3Rv4MXl #JPM24

We will be presenting at the Oppenheimer & Co. Inc. Annual Healthcare Life Sciences Conference on February 14. We’re excited to connect with #investors to showcase our plans to advance a new class of precision #geneticmedicine. Learn more: bit.ly/3SnWwYc #OPCOLifeSciences